Entering the age of the $1 million medicine
Reuters analysis talks about drug development for what they call “orphan diseases”, which are those relating to very small segments of the population.
Because only a small percentage of the population has these problems, drug companies have been able to charge what they like. Rare diseases therefore are attracting a lot of attention from various pharma players.
It seems though that health care providers are rebelling and the pressure is on to shake out pricing
Analysis: Entering the age of the $1 million medicine | Reuters.
Related Posts
Injecting botox into stomach does not promote weight loss
Tissue engineers report knee cartilage repair success with new biomaterial
New implant replaces impaired middle ear
Reader’s Digest Interview on Aging and Longevity Science
Stem cells found to heal damaged artery in lab study
Cancer suppressor gene links metabolism with cellular aging